Buchumschlag

Tau PET Imaging With [18F]MK‐6240: Limited Affinity for Primary Tauopathies and High Specificity for Alzheimer's Disease

Fuente: Wiley Open Access

Gespeichert in:

Bibliographische Detailangaben
Hauptverfasser:	Thomas Gérard, Lise Colmant, Vincent Malotaux, Yasmine Salman, Lara Huyghe, Lisa Quenon, Emilien Boyer, Laurence Dricot, Adrian Ivanoiu, Renaud Lhommel, Bernard Hanseeuw
Format:	Artículo Open Access
Veröffentlicht:	Wiley 2025
Schlagworte:	European Journal of Neurology
Online-Zugang:	Acceder al recurso
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Ähnliche Einträge

The atrophy of specific amygdala subnuclei is associated with temporal tauopathy in preclinical AD individuals
von: Yasmine Salman, et al.
Veröffentlicht: (2024)

Association between short‐term memory binding performance and tau burden in the medial temporal lobe
von: Lara Huyghe, et al.
Veröffentlicht: (2024)

Targeting pre‐symptomatic AD individuals: Deep cognitive assessment and plasma biomarkers to predict tau aggregation
von: Lisa Quenon, et al.
Veröffentlicht: (2025)

Associations between deep category fluency phenotyping and early tau aggregation in the medial temporal lobe
von: Lisa Quenon, et al.
Veröffentlicht: (2024)

Discrimination tasks increase the value of plasma p ‐tau217 to predict presymptomatic Alzheimer's disease
von: Lara Huyghe, et al.
Veröffentlicht: (2025)

Discrimination tasks increase the value of plasma p ‐tau217 to predict presymptomatic Alzheimer's disease
von: Lara Huyghe, et al.
Veröffentlicht: (2025)

VeraBIND Tau test, a novel plasma assay for active tau pathology, identifies individuals with positive tau‐PET signal, regardless of amyloid status
von: Bernard J Hanseeuw, et al.
Veröffentlicht: (2025)

Path integration deficits are related to Alzheimer’s disease pathology
von: Lise Colmant, et al.
Veröffentlicht: (2024)

Specific atrophy patterns distinguish tau and TDP‐43 pathology: a longitudinal MRI ante‐mortem study
von: Yasmine Salman, et al.
Veröffentlicht: (2025)

Olfactory decline tracks central‐to‐peripheral spread of tau pathology in Alzheimer's disease
von: Kamar Bouchoucha, et al.
Veröffentlicht: (2026)

Predictive Value of Plasma Biomarkers in Tau‐ PET Transitions
von: Jonathan Graff‐Radford, et al.
Veröffentlicht: (2025)

Temporal Modeling of Amyloid and Tau Trajectories in Alzheimer's Disease Using PET and Plasma Biomarkers
von: Christopher A. Brown, et al.
Veröffentlicht: (2026)

Timing of Changes in Alzheimer's Disease Plasma Biomarkers as Assessed by Amyloid and Tau PET Clocks
von: Marta Milà‐Alomà, et al.
Veröffentlicht: (2025)

Uncovering Image‐Driven Subtypes with Distinct Pathology and Clinical Course in Autopsy‐Confirmed Four Repeat Tauopathies
von: Ryota Satoh, et al.
Veröffentlicht: (2025)

IgG4‐Related Disease Associated With Myotonic Dystrophy Type 2
von: Antoine Pegat, et al.
Veröffentlicht: (2025)

Dual‐Phase C‐11 PiB PET Images for Detecting Tau Pathology in Cerebral Amyloid Angiopathy
von: Meng‐Ting Chiang, et al.
Veröffentlicht: (2025)

Towards new perspectives: A scoping review and meta‐synthesis to redefine brain health for multiple sclerosis
von: Olivia Wills, et al.
Veröffentlicht: (2024)

Tau Pathology in Alzheimer's Disease Uniquely Affects Sulcal Depths
von: Samira A. Maboudian, et al.
Veröffentlicht: (2026)

Microglial Reactivity Correlates with Presynaptic Loss Independent of β‐Amyloid and Tau
von: Guoyu Lan, et al.
Veröffentlicht: (2024)

Midlife Steroid‐Binding Globulin Levels and In Vivo Neuroimaging Measures of Tau in Older Men and Women
von: Rachel F. Buckley, et al.
Veröffentlicht: (2025)

Deciphering the Role of Ubiquitination in Tauopathies
von: Axelle A.T. Vanparys, et al.
Veröffentlicht: (2024)

Use of FDG ‐ PET in Balamuthia mandrillaris Amebic Encephalitis
von: Kristoffer E. Leon, et al.
Veröffentlicht: (2025)

Cerebral Amyloidoma: An Update Following “Fixation Duress” on PET
von: Shervin Pejhan, et al.
Veröffentlicht: (2026)

Reply to “Cerebral Amyloidoma: An Update Following ‘Fixation Duress’ on PET ”
von: J. Alexander Fraser, et al.
Veröffentlicht: (2026)

Plasma pTau181 Reveals a Pathological Signature that Predicts Cognitive Outcomes in Lewy Body Disease
von: Carla Abdelnour, et al.
Veröffentlicht: (2024)

Amyloid PET in Sporadic Early‐ Versus Late‐Onset Alzheimer's Disease: Comparison of the LEADS and ADNI Cohorts
von: Julien Lagarde, et al.
Veröffentlicht: (2025)

Inhibition of Bone Morphogenetic Protein Signaling Prevents Tau Pathology in iPSC Derived Neurons and PS19 Mice
von: Amira Affaneh, et al.
Veröffentlicht: (2024)

Cognitive phenotype and neurodegeneration associated with Tau in Huntington's disease
von: Saul Martinez‐Horta, et al.
Veröffentlicht: (2024)

Outcome measures for ambulant children with cerebral palsy after limb extremity orthopedic surgery: What should be measured and who should decide?
von: Elizabeth R. Boyer
Veröffentlicht: (2026)

Tau maturation in the clinicopathological spectrum of Lewy body and Alzheimer's disease
von: Sanaz Arezoumandan, et al.
Veröffentlicht: (2024)

Brain‐Derived Tau as an Outcome Marker in Guillain‐Barré Syndrome: A Retrospective Cohort Study
von: Brynhildur Hafsteinsdóttir, et al.
Veröffentlicht: (2025)

Reassessing BD‐Tau as a Prognostic Biomarker in Guillain‐Barré Syndrome: Methodological Considerations for Clinical Interpretation
von: Umar Aziz
Veröffentlicht: (2025)

Preserved unfamiliar face identity discrimination ability in Alzheimer’s disease: electrophysiological evidence
von: Justine David, et al.
Veröffentlicht: (2024)

Real‐life experience with disease‐modifying drugs in hereditary transthyretin amyloid polyneuropathy: A clinical and electrophysiological appraisal
von: Hadia Rebouh, et al.
Veröffentlicht: (2024)

ALS plasma biomarkers reveal neurofilament and pTau correlate with disease onset and progression
von: Eleanor V. Thomas, et al.
Veröffentlicht: (2025)

Higher Amyloid and Tau Burden Is Associated With Faster Decline on a Digital Cognitive Test
von: Jessie Fanglu Fu, et al.
Veröffentlicht: (2025)

Response to Letter to the Editor Regarding “Brain‐Derived Tau as an Outcome Marker in Guillain‐Barré Syndrome: A Retrospective Cohort Study”
von: Brynhildur Hafsteinsdóttir
Veröffentlicht: (2025)

Synaptic Density Reductions in MSA: A Potential Biomarker Identified Through [18F]SynVesT‐1 PET Imaging
von: Jian Li, et al.
Veröffentlicht: (2025)

Intraepineurial Fat Fraction: A Novel MR Neurography‐Based Biomarker in Transthyretin Amyloidosis Polyneuropathy
von: Eva Sole Cruz, et al.
Veröffentlicht: (2025)

DMCN 2024 highlights: Quality research, epidemiology, and parental perspective
von: Bernard Dan
Veröffentlicht: (2024)